# Phase 2F final independent migration review

Review date: 2026-07-22 UTC  
Reviewer role: independent Classic-to-Renewed UHMS migration reviewer  
Scope: consolidated Phase 2F patient-pilot mapping-contract package only

## Verdict

**PASS**

Critical: **0**. High: **0**. Medium: **0**. Low: **0**.

Phase 2F satisfies its specification exit boundary. Phase 3 migration-foundation work may begin, but no patient pilot, importer, database write or commit-mode execution is authorized. The package is a reviewed contract, not evidence that the future migration runtime is safe or production-ready.

## Review boundary and evidence

I reviewed `AGENTS.md`, the complete Phase 2F owner directive, `APPROVED_DECISION_SPECIFICATIONS.md`, `DECISIONS.md`, `OPEN_QUESTIONS.md`, the migration plan/dependency/entry records, target inventory/constraint/fingerprint/creation/side-effect evidence, all Phase 2A-2E exit/readiness records and the relevant normative Phase 2A-2E machine specifications. I reviewed the complete Phase 2F package, including all final documents, machine specifications, specialist drafts, the prior independent-review draft and the focused test.

The reviewed Phase 2F package contains:

- 26 required top-level Markdown documents;
- 21 required JSON specifications, all at version `2F.1.0` and parseable;
- 66 contiguous Cohort A fixtures, `A-001` through `A-066`;
- 24 ordered Cohort B strata with a maximum of 148 protected roots;
- 11 distinct Cohort C comparison branches;
- 33 uniquely owned source-field mappings: 15 Phase 2C, seven Phase 2D and 11 Phase 2E;
- 24 dependency stages, numbered 0 through 23;
- eight atomicity records covering patient core/link, alias, contact, insurance history/current and cross-resource/visibility safeguards;
- 13 idempotency outcomes;
- 16 target-collision branches;
- 10 crash-boundary recovery contracts and 24 lifecycle states;
- 49 named mandatory safety-zero measures; and
- 25 Phase 3 foundation capabilities.

I did not connect to or query Classic or renewed UHMS. I made no database, application, schema, configuration or implementation change. This final review replaces only this independent-review draft.

## Focused validation result

Command:

`php artisan test tests/Unit/LegacyMigration/Evidence/Phase2FSpecificationConsistencyTest.php --colors=never`

Result: **15 tests passed, 18,449 assertions, exit code 0**.

No broad application test suite was run. The focused suite proves package enumeration and JSON parsing; exact `legacy_uhms`/`uuhms` read-only boundaries; non-executable flags; 33-field ownership; complete fixture structure and exact outcomes; Cohort B fail-closed readiness; state and insurance initialization blockers; dependency ordering; atomicity/idempotency/recovery structure; reconciliation and safety zeroes; quarantine/collision invariants; upstream exception and contract resolution; complete privacy-scan scope; and Phase 3 traceability.

## Prior finding dispositions independently verified

| Prior finding | Final disposition and evidence |
|---|---|
| High 1 - incomplete synthetic scenarios | **Closed.** `patient_pilot_scenarios.json` now contains 66 complete synthetic-only records. Each record has exact patient and insurance source-field state, alias/child/remediation/target/fault/orphan inputs, explicit per-domain outcomes, exception precedence, provenance cardinalities, instantiated zero-tolerance reconciliation equations and all 49 safety zeroes. No fixture authorizes or reports a Phase 2F database write. |
| High 2 - dry-run sequence unreachable | **Closed.** `P2F-STAGE-10` treats unresolved identity/state prerequisites as coded patient-and-chain quarantine and explicitly keeps stages 11-23 reachable. `P2F-STAGE-18` withholds unresolved current insurance representation while preserving every history outcome and keeps stages 19-23 reachable. Unsafe invention/defaulting remains a stop. |
| High 3 - `INS-CONS-010` weakened | **Closed.** `PILOT-INS-INIT-003`, `-005`, `-007` and `-008` require `insurance_tier_id`, `card_holder_insurance_id`, `policy_number` and `ccc_code` to remain null/not evidenced exactly under `INS-CONS-010`. The human initialization matrix states the same rule. |
| High 4 - patient state matrix incomplete/mislabelled | **Closed.** `patient_pilot_state_matrix.json` has 20 records with installed type, allowed values, semantics, installed default, default-safety rationale, Classic evidence, approved policy, target initialization, recommendation/rationale, approval state, existing-target behavior, exception, reconciliation and Phase 3 requirement. `PILOT-STATE-020` makes the coherent tuple an explicit commit blocker and does not mislabel the recommendation as source evidence. |
| High 5 - rollback/resume incomplete | **Closed.** All 10 mandated boundaries include durable facts, retry, duplicate prevention, rollback feasibility, compensation, checkpoint behavior, reconciliation proof, operator action and disposition. The contract explicitly rejects universal hard deletion and protects existing-target links from target mutation. |
| High 6 - privacy regression scope incomplete | **Closed.** `P2F-PRIVACY-SCANNER-2` covers every file under `docs/legacy-migration/**` plus the focused Phase 2F test. The independently recomputed ordinal path manifest contains 286 files and matches SHA-256 `fa756afcdc1d5a96926351997d23f25cca5fde95db5bd667aaca96793e9fb774`; coverage difference and unallowlisted findings are zero. Diagnostics are redacted by contract. |
| Medium 1 - Cohort B readiness overstated | **Closed.** `patient_pilot_source_selection_rules.json` declares `dry_run_ready=false`, `future_commit_ready_count=0`, frozen predicates `0/24`, and `BLOCKED_PENDING_24_HASH_BOUND_PREDICATES_AND_REQUIRED_CAPACITY_QUERIES_AT_PINNED_SNAPSHOT`. The readiness matrix says “Not ready for dry-run.” |
| Medium 2 - exception/quarantine idempotency collapsed | **Closed.** `PILOT-IDEM-009` identifies an exception record using its exception code; `PILOT-IDEM-013` independently identifies the single typed quarantine root without an exception code. Multiple ordered exceptions do not create multiple chain identities. |
| Medium 3 - collision routing/coverage over-broad | **Closed.** `PILOT-COLL-012` routes immutable comparison evidence to `LEGACY-PATIENT-CHILD-CONTACT-012`; `PILOT-COLL-016` separately routes an attempted/detected mutation to `LEGACY-PATIENT-CHILD-TARGET-036` with the contact-mutation secondary exception. Cohort C separately covers contact difference (`C-007`) and multiple primaries (`C-011`). Existing-target deltas remain zero. |
| Medium 4 - Phase 3 capability traceability incomplete | **Closed.** All 25 capabilities reference existing normative Phase 2F IDs and specify minimum tests. In particular, `PHASE3-FOUND-014` and `PHASE3-FOUND-023` now reference the coherent patient-state contract `PILOT-STATE-020`; persistence, insurance, idempotency, checkpoint, resume and compensation capabilities also reference their governing atomicity/idempotency/recovery contracts. |

## Confirmed safety and integrity controls

- All 21 Phase 2F specifications declare source connection `legacy_uhms`, exact Classic database `uuhms`, source read-only, approved target read-only, `implementation_authorized=false` and `contains_raw_phi=false`.
- The Phase 2F tree contains documentation and JSON only. The only Phase 2F code artifact is the focused read-only specification test; no importer, persistence service, state/crosswalk/provenance/quarantine/reconciliation table, migration, schema change, allocator, UI, seeder, queue/synchronization/cutover runtime or writing configuration was introduced.
- Cohort A fixtures are clearly namespaced `SYNTHETIC-ONLY-P2F`; their values are synthetic atoms or approved categorical literals, not copied or perturbed patient records.
- Cohort B is deterministic and bounded, but honestly blocked until all 24 normalized predicates and required capacity queries are snapshot/hash-bound. No unremediated source patient is called commit-ready.
- Patient identity is classified and sealed before alias, demographics, contact or insurance processing. No child may rewrite identity or release before its valid parent.
- Existing-target patients, contacts and memberships are comparison-only and immutable. Collision outcomes prohibit suffixing, target substitution, merge-pointer following, deletion/recreation and target enrichment.
- Every insurance source row has a protected history/provenance outcome. Exact duplicate source rows retain separate lineage, and at most one current representation is permitted per resolved patient/provider group.
- Patient and insurance database/model defaults are not migration authority. Unapproved patient state, `member_type`, active/primary state or timestamps block commit while allowing classified dry-run accounting.
- Rerun checks resolve prior compatible mappings before allocation; the same patient and patient number are retained; alias/contact/membership duplicates are prohibited; source, contract and target drift fail closed.
- Reconciliation requires 100% classification and zero unexplained difference. Expected nonzero exceptions remain coded, rooted and owned rather than being reported as successful records.
- Dry-run writes, Classic writes, target writes, operational service calls, queues, notifications, security propagation, billing/accounting/stock effects and existing-target mutations are mandatory zeroes.

## Residual prerequisites and authorization boundary

Phase 2F completion does not make Cohort B executable and does not authorize patient persistence. The following remain mandatory before any later commit pilot: the D-101 least-privilege account on exact `uuhms`; frozen protected cohort predicates/manifest; protected and accepted name/required-field remediation; approved coherent patient-state/timestamp tuple; approved insurance `member_type`, active/primary/timestamp representation; approved provider-crosswalk runtime inputs; protected HMAC/crosswalk/remediation/provenance/quarantine/reconciliation/audit stores; safe patient-number allocation; migration-specific atomic persistence; complete side-effect isolation; fresh collision checks; tested idempotency/checkpoint/resume/compensation; zero-difference dry-run evidence; independent Phase 3 review; and separate explicit commit-pilot authorization.

The valid next step is Phase 3 migration-foundation implementation within the exact restrictions in `PHASE_2F_EXIT_REPORT.md`. Phase 3 must not implement a patient importer or execute this pilot.

**PASS**
